Novel method for the synthesis of dinucleoside-(N3′ → P5′)-phosphoramidothioates

[1]  Tomasz Pawlak,et al.  Assignment of the absolute configuration at stereogenic phosphorus atoms in P-diastereomers of dithymidyl-(N3′→P5′)-phosphoramidothioate , 2016 .

[2]  J. Baraniak,et al.  Synthesis of PS/PO-chimeric oligonucleotides using mixed oxathiaphospholane and phosphoramidite chemistry. , 2015, Organic & biomolecular chemistry.

[3]  H. Couthon-Gourvès,et al.  Atherton–Todd reaction: mechanism, scope and applications , 2014, Beilstein journal of organic chemistry.

[4]  R. Juliano,et al.  The chemistry and biology of oligonucleotide conjugates. , 2012, Accounts of chemical research.

[5]  P. Murat,et al.  Recent developments in oligonucleotide conjugation. , 2010, Chemical Society reviews.

[6]  B. Herbert,et al.  Targeting critical steps of cancer metastasis and recurrence using telomerase template antagonists. , 2009, Biochimica et biophysica acta.

[7]  P. Guga.  P-chiral oligonucleotides in biological recognition processes. , 2007, Current topics in medicinal chemistry.

[8]  J. Shay,et al.  Telomerase therapeutics for cancer: challenges and new directions , 2006, Nature Reviews Drug Discovery.

[9]  K. Pongracz,et al.  A new approach to oligonucleotide N3' → P5' phosphoramidate building blocks , 2006 .

[10]  E. Blackburn.  Telomerase and Cancer , 2005, Molecular Cancer Research.

[11]  R. Kaczmarek,et al.  Synthesis of nucleoside–amino acid conjugates containing boranephosphate, boranephosphorothioate and boranephosphoramidate linkages☆ , 2004 .

[12]  K. Collins,et al.  Telomere maintenance and disease , 2003, The Lancet.

[13]  C. Harley,et al.  A novel telomerase template antagonist (GRN163) as a potential anticancer agent. , 2003, Cancer research.

[14]  C. Harley,et al.  Oligonucleotide N3′ → P5′ Thio-phosphoramidate Telomerase Template Antagonists as Potential Anticancer Agents , 2003, Nucleosides, nucleotides & nucleic acids.

[15]  Jens Kurreck,et al.  Antisense technologies. Improvement through novel chemical modifications. , 2003, European journal of biochemistry.

[16]  J. Shay,et al.  Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors , 2002, Oncogene.

[17]  C. Harley,et al.  Telomerase inhibitors--oligonucleotide phosphoramidates as potential therapeutic agents. , 2001, Nucleosides, nucleotides & nucleic acids.

[18]  M. Egli,et al.  Synthetic oligonucleotides as RNA mimetics: 2′-modified RNAs and N3′→P5′ phosphoramidates , 2000, Cellular and Molecular Life Sciences CMLS.

[19]  F. Eckstein.  Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? , 2000, Antisense & nucleic acid drug development.

[20]  S. Gryaznov.  Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents. , 1999, Biochimica et biophysica acta.

[21]  K. Pongracz,et al.  Oligonucleotide N3′→P5′ thiophosphoramidates: synthesis and properties , 1999 .

[22]  W. Stec,et al.  Synthesis of 2‘,3‘-Dideoxyribonucleoside-3‘-N-(2-oxo-1,3,2-oxathiaphospholanes) and Their Reactions with 5‘-OH Nucleosides and Fluoride Ion , 1999 .

[23]  S. Mccurdy,et al.  N3'-->P5' Oligodeoxyribonucleotide Phosphoramidates: A New Method of Synthesis Based on a Phosphoramidite Amine-Exchange Reaction. , 1997, The Journal of organic chemistry.

[24]  B. Calabretta,et al.  Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Lloyd,et al.  Synthesis of oligodeoxyribonucleotide N3'-->P5' phosphoramidates. , 1995, Nucleic acids research.

[26]  S. Gryaznov,et al.  Oligodeoxyribonucleotide N3'.fwdarw.P5' Phosphoramidates: synthesis and Hybridization Properties , 1994 .

[27]  H. Openshaw,et al.  174. Studies on phosphorylation. Part II. The reaction of dialkyl phosphites with polyhalogen compounds in presence of bases. A new method for the phosphorylation of amines , 1945 .